Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $36.00

Definium Therapeutics (NASDAQ:DFTX) had its price objective raised by Royal Bank Of Canada from $20.00 to $36.00 in a research report released on Friday morning, Marketbeat.com reports. The firm currently has an outperform rating on the stock.

Several other analysts have also commented on DFTX. Lifesci Capital raised shares of Definium Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Jones Trading began coverage on Definium Therapeutics in a research note on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Canaccord Genuity Group upped their target price on Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $32.11.

Definium Therapeutics Trading Up 2.5%

Shares of DFTX stock opened at $17.40 on Friday. The stock has a 50-day simple moving average of $13.16 and a 200 day simple moving average of $11.48. The stock has a market capitalization of $1.71 billion, a P/E ratio of -8.53 and a beta of 2.57. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $18.12. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). On average, sell-side analysts expect that Definium Therapeutics will post -1.35 earnings per share for the current fiscal year.

Insider Activity at Definium Therapeutics

In related news, CEO Robert Barrow sold 25,791 shares of the stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the sale, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. This represents a 3.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the transaction, the insider directly owned 282,576 shares in the company, valued at approximately $3,715,874.40. This trade represents a 3.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 42,667 shares of company stock valued at $561,071. Company insiders own 2.26% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP lifted its position in Definium Therapeutics by 31.9% in the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after buying an additional 828,067 shares in the last quarter. Commodore Capital LP increased its stake in shares of Definium Therapeutics by 10.5% in the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after acquiring an additional 475,000 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Definium Therapeutics during the third quarter worth $4,337,000. Rosalind Advisors Inc. boosted its position in Definium Therapeutics by 78.6% during the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after purchasing an additional 330,000 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in Definium Therapeutics by 424.9% during the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after purchasing an additional 239,965 shares during the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.